Pretreatment neutrophil-to-lymphocyte/monocyte-to-lymphocyte ratio as prognostic biomarkers in glioma patients

Sher Ting Chim, Paul Sanfilippo, Terence J. O'Brien, Kate J. Drummond, Mastura Monif

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


Objectives: To evaluate the ability for pre-treatment NLR and MLR to predict overall survival (OS) and modified Rankin Scale (mRS) and to explore their relationship with clinicopathological parameters. Methods: Retrospective analysis of pretreatment NLR and MLR from 64 glioma patients. Results: Higher pretreatment NLR (>4.7) predicted higher mean admission mRS (p < 0.001) and 6-month mRS (p = 0.02). Higher pretreatment MLR (>0.35) was a risk factor for poorer OS in glioma patients (p = 0.024). Higher pretreatment NLR was significantly associated with larger tumor diameter (p = 0.02). Conclusion: NLR and MLR can serve as prognostic markers to predict functional outcomes and OS in glioma patients

Original languageEnglish
Article number577754
Number of pages11
JournalJournal of Neuroimmunology
Publication statusPublished - 15 Dec 2021


  • glioma
  • MLR
  • NLR
  • prognosis

Cite this